Suketu Upadhyay

October 17, 2026

Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.

October 17, 2026

Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.

October 17, 2026

Zimmer Biomet Extends Exclusive Distribution Deal with Think Surgical. Zimmer Biomet has extended its exclusive distribution agreement with Think Surgical to supply the wireless TMINI miniature robotic system. The deal expands the company's reach in surgical robotics and aligns with its strategy of partnering with innovative technology providers. It follows strong Q2 results that benchmarked well against peers in the surgical equipment sector, reinforcing Zimmer Biomet’s competitive position within the S&P 500.